Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.
Happy Friday! We here on the healthcare team have had a big week of coronavirus vaccine and treatment developments and preparing for an election that's less than two weeks away.
Andrew tuned into the day-long affair, catching up on all the plans, including vaccine cards that track who's ready for their second shots (I'm not confident I will keep track of mine). Another challenge: vaccine hesitancy could limit how many people get a shot, if/when we get effective vaccines.
Direct-to-consumer healthcare startup Thirty Madison also raised tens of millions in the third quarter, bringing in $47 million from investors including pharma giant Johnson & Johnson.
Blake got a look at the presentation the company used to win investors over on a company that prescribes and ships medications for conditions like migraines, acid reflux, and hair loss.
How Oscar and Clover have performed financially over the years
We're gearing up for the public debut of health insurer Clover Health in 2021 via SPAC.
So we thought it might be a good time to take a trip down memory lane, wading through years of insurance filings, to get a look at how Clover and rival Oscar Health have performed over the years in two key ways: enrollment and profits or losses.
Both companies posted profits in the first half of this year, but it'll be interesting to see how they fare through the rest of 2020. Insurers have made a windfall as members postponed medical care in the early days of the pandemic.
